Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2019-04-11 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
河南海王银河医药有限公司2018年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report' and includes detailed financial statements such as the balance sheet, income statement, cash flow statement, and notes to the financial statements for the fiscal year ending December 31, 2018. It contains an auditor's opinion, basis for the opinion, management's responsibility, and auditor's responsibility sections, which are typical components of a standalone audit report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. There is no indication that this is an annual report (10-K) or interim report, nor is it a certification or announcement. Therefore, the document fits the definition of an Audit Report / Information (AR).
2019-04-11 Chinese
前次募集资金使用情况报告
Capital/Financing Update Classification · 95% confidence The document is titled '前次募集资金使用情况报告' which translates to 'Report on the Use of Previous Fundraising Proceeds'. It details the amount of funds raised, the timing of fund receipt, usage of the funds, and reconciles actual investment amounts with committed amounts. It also references approval by the China Securities Regulatory Commission and includes detailed tables on fund usage. The content focuses on the use of capital raised through a non-public stock issuance, including amounts, timing, and project investment status. There is no indication that this is an announcement of a report publication or a brief summary; rather, it is a detailed report on capital usage. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is 2553 characters, which is relatively short but contains substantive financial and capital usage data, not just an announcement or certification. Therefore, the best classification is CAP with high confidence.
2019-04-11 Chinese
第七届董事局第三十一次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Shenzhen Haiwang Bioengineering Co., Ltd. It discusses the approval of a non-public stock issuance plan, including specifics on the stock type, issuance quantity, pricing, lock-up periods, and related shareholder approvals. The document includes voting results and mentions that these resolutions will be submitted to the shareholders' meeting for approval. The content focuses on board decisions regarding capital raising and stock issuance, which is characteristic of a Capital/Financing Update. It is not a full financial report, audit, or earnings release, nor is it a simple announcement of a report publication. The document length and detail confirm it is not a brief announcement but a substantive update on financing activities.
2019-04-11 Chinese
独立董事关于2019年非公开发行股票相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' opinion on matters related to a non-public stock issuance in 2019, including the fairness of the transaction, compliance with laws, and shareholder return planning for 2019-2021. It is a formal opinion letter rather than a full report or announcement of financial results. The document is short (1135 characters) and focuses on governance and transaction fairness related to a capital raising event. It does not contain financial statements or detailed financial data, nor is it a simple announcement of a report. It is not a management report or earnings release. The content aligns best with a Capital/Financing Update (CAP) as it discusses a non-public stock issuance and related shareholder matters.
2019-04-11 Chinese
本次非公开发行股票摊薄即期回报对公司主要财务指标的影响及填补回报采取的措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haier Bioengineering Co., Ltd. regarding a non-public issuance of shares and its impact on the company's key financial indicators, including dilution of immediate returns to shareholders. It includes analysis of financial metrics, risk warnings, measures to compensate for dilution, and commitments from the board and controlling shareholders. The document references regulatory requirements from the China Securities Regulatory Commission and includes detailed financial assumptions and projections related to the capital raising. It is not a full annual or interim report, nor an earnings release or audit report. It is a capital/financing update focused on the non-public share issuance and related financial impact and commitments. The document length (6323 characters) and content indicate it is the actual announcement of the financing event and its implications, not merely a notice or a certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-04-11 Chinese
关于调整收购河南海王银河医药有限公司少数股东股权协议的补充公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the adjustment of an acquisition agreement for minority shareholders' equity in Henan Haiwang Yinhe Pharmaceutical Co., Ltd. It includes audited financial data for 2017 and 2018, references to an audit report for 2018, and discusses changes in performance targets and pricing standards. The document is not the audit report itself but a supplementary announcement related to the acquisition agreement adjustment, including financial data audited by a qualified accounting firm. It is a regulatory announcement about a capital transaction and acquisition agreement adjustment, with detailed financial and legal explanations, but it does not constitute a full audit report or annual report. Given the content and context, this fits best under Capital/Financing Update (CAP) as it relates to changes in acquisition terms and equity transactions involving minority shareholders.
2019-04-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.